Study discovers new HIV vaccine target

May 12, 2016, NIH/National Institute of Allergy and Infectious Diseases
A model of the VRC34.01 antibody (green and yellow) bound to the fusion peptide (red) on a spike on HIV's surface (gray). Credit: NIAID

A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell. The study was led by scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of NIH.

The new target is a part of HIV called the fusion peptide, a string of eight amino acids that helps the virus fuse with a cell to infect it. The fusion peptide has a much simpler structure than other sites on the virus that HIV vaccine scientists have studied.

The scientists first examined the blood of an HIV-infected person to explore its ability to stop the virus from infecting . The blood was good at neutralizing HIV but did not target any of the vulnerable spots on the virus where broadly neutralizing HIV antibodies (bnAbs) were known to bind.

The researchers isolated a powerful bnAb in the blood that they named VRC34.01, and found that it binds to the fusion peptide and a sugar molecule. The scientists then crystallized the antibody while it was bound to the virus. This allowed them to characterize in atomic-level detail how VRC34.01 attaches to HIV and revealed that the antibody stops the from infecting a cell by binding to a key cell-surface molecule.

The scientists also report that it is not unusual for the immune system to try to stop HIV from infecting a cell by attacking the fusion peptide. When they screened the blood of 24 HIV-infected volunteers, they found that samples from 10 people targeted a similar binding site as VRC34.01.

The researchers are now working to create a designed to elicit antibodies similar to the VRC34.01 antibody.

The study is published in the journal Science.

Explore further: Researchers identify potent antibodies against HIV

More information: "Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody," DOI: 10.1126/science.aae0474

Related Stories

Researchers identify potent antibodies against HIV

April 6, 2016
It's been known for some time that the immune system can produce antibodies capable of "neutralizing" HIV, and stopping the AIDS-causing virus dead in its tracks.

Scientists discover HIV antibody that binds to novel target on virus

September 3, 2014
An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. The site straddles two proteins, gp41 and gp120, that jut out of the ...

Researchers unravel pathways of potent antibodies that fight HIV infection

March 3, 2016
One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates.

Researchers determine how antibody recognizes key sugars on HIV surface

November 23, 2011
HIV is coated in sugars that usually hide the virus from the immune system. Newly published research reveals how one broadly neutralizing HIV antibody actually uses part of the sugary cloak to help bind to the virus. The ...

Researchers find alternative pathways to HIV antibodies

May 4, 2016
The immune system appears to hamper an investigational vaccine from inducing antibodies that protect against HIV infection, but there may be ways to overcome this impediment, according to research led by the Duke Human Vaccine ...

New TSRI study shows HIV structure in unprecedented detail

March 3, 2016
A new study from scientists at The Scripps Research Institute (TSRI) describes the high-resolution structure of the HIV protein responsible for recognition and infection of host cells.

Recommended for you

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

Scientists unveil promising new HIV vaccine strategy

November 26, 2018
A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests.

Influential U.S. panel backs PrEP HIV-prevention pills

November 20, 2018
(HealthDay)—For the first time, a highly influential panel of experts says doctors should offer a daily pill to prevent HIV transmission to people who are at high risk for infection with the AIDS-causing virus.

Majority of HIV persistence during ART due to infected cell proliferation

November 17, 2018
A majority of the HIV-infected cells that persist in HIV-infected individuals even during suppressive antiretroviral therapy (ART) originated from cellular proliferation, not viral replication, according to new research published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.